Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib

Leukemia Research

Volumn 35, Issue 11, 2011, Pages 1527-1529

  Soverini, Simona ^a   Gnani, Alessandra ^a   De Benedittis, Caterina ^a   Castagnetti, Fausto ^a   Gugliotta, Gabriele ^a   Iacobucci, Ilaria ^a   Palandri, Francesca ^a   Rosti, Gianantonio ^a   Testoni, Nicoletta ^a   Luatti, Simona ^a   Marzocchi, Giulia ^a   Baccarani, Michele ^a   Martinelli, Giovanni ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Bcr Abl; Chronic myeloid leukemia; Kinase domain mutations; Major molecular response; Nilotinib

Indexed keywords

NILOTINIB;

ADULT; AGED; ARTICLE; BCR ABL GENE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE; GENE MUTATION; GENE SEQUENCE; HUMAN; MALE; MOLECULAR CLONING; MUTATIONAL ANALYSIS; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; POLYMERASE CHAIN REACTION; PYRIMIDINES; TREATMENT OUTCOME;

EID: 80053932948     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.05.029     Document Type: Article

References (11)

1. Sherbenou D.W., Wong M.J., Humayun A., McGreevey L.S., Harrell P., Yang R., et al. Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib. Leukemia 2007, 21:489-493.
2. Khorashad J.S., de Lavallade H., Apperley J.F., Milojkovic D., Reid A.G., Bua M., et al. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol 2008, 26:4806-4813.
3. Willis S.G., Lange T., Demehri S., Otto S., Crossman L., Niederwieser D., et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005, 106:2128-2137.
4. Rosti G., Palandri F., Castagnetti F., Breccia M., Levato L., Gugliotta G., et al. Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood 2009, 114:4933-4938.
5. Cortes J.E., Jones D., O'Brien S., Jabbour E., Konopleva M., Ferrajoli A., et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 2010, 28:392-397.
6. Saglio G., Kim D.W., Issaragrisil S., le Coutre P., Etienne G., Lobo C., et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010, 362:2251-2259.
7. Soverini S., Martinelli G., Amabile M., Poerio A., Bianchini M., Rosti G., et al. Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib. Clin Chem 2004, 50:1205-1213.
8. Bradeen H.A., Eide C.A., O'Hare T., Johnson K.J., Willis S.G., Lee F.Y., et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006, 108:2332-2338.
9. Ray A., Cowan-Jacob S.W., Manley P.W., Mestan J., Griffin J.D. Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood 2007, 109:5011-5015.
10. von Bubnoff N., Manley P.W., Mestan J., Sanger J., Peschel C., Duyster J. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood 2006, 108:1328-1333.
11. Chu S., Xu H., Shah N.P., Snyder D.S., Forman S.J., Sawyers C.L., et al. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 2005, 105:2093-2098.